Showing 1951-1960 of 2314 results for "".
- Study: Warning Signs of Sight Loss Could be Identified Before Vision Deteriorateshttps://modernod.com/news/study-warning-signs-of-sight-loss-could-be-identified-before-vision-deteriorates/2480502/A new study has shown that the signs of age related macular degeneration can set in earlier than previously thought – even before patients begin to lose their sight. The findings open the door for research into earlier treatment that could help slow down the onset of the condition the most
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Diseasehttps://modernod.com/news/nicoxs-positive-post-hoc-results-from-ncx-4251-phase-2b-mississippi-trial-suggest-path-forward-in-dry-eye-disease/2480480/Nicox SA announced positive post hoc results from its Mississippi Phase 2b clinical trial suggesting that once-daily dosed NCX 4251, fluticasone propionate ophth
- Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-publication-in-ophthalmology-of-onset-2-phase-3-data-on-tyrvaya-varenicline-solution-nasal-spray/2480446/Oyster Point Pharma announced that results from the multicenter, randomized, double-masked, vehicle-controlled phase 3 clinical trial (The ONSET-2 study) of Tyrvaya Nasal Spray (varenicline solution) have been published in Ophthalmology.1 
- In-Office MGD Procedure Market is Largely Untapped, Survey Showshttps://modernod.com/news/in-office-mgd-procedure-market-is-largely-untapped-survey-shows/2480424/Doctors in the US and Europe diagnose approximately two-thirds of their dry eye patients with evaporative dry eye but treat very few of them in the office for meibom
- Unity Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks in Phase 1 Study of Patients with Advanced Vascular Eye Diseasehttps://modernod.com/news/unity-biotechnology-announces-improvement-in-visual-acuity-sustained-through-24-weeks-in-phase-1-study-of-patients-with-advanced-vascular-eye-disease/2480419/Unity Biotechnology announced 24-week data from its phase 1 single ascending dose (SAD) safety study of UBX1325 in patients wit
- Regeneron's Antibody Cocktail Offers Long-Term Protection Against COVID-19https://modernod.com/news/regenerons-antibody-cocktail-offers-long-term-protection-against-covid-19/2480418/Regeneron Pharmaceuticals said Monday that a single dose of the antibody cocktail REGEN-COV (casirivimab and imdevimab) reduced the risk of contracting COVID-19 by 81.6% in the two- to eight-month period after it was given. The result is in line with an
- Aldeyra Therapeutics Announces Achievement of Primary Endpoint in Phase 2 Clinical Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-in-phase-2-clinical-trial-in-dry-eye-disease/2480392/Aldeyra Therapeutics announced achievement of the primary endpoint of ocular redness in a randomized, double-masked, vehicle-controlled phase 2 clinical trial in patients with dry eye disease. The clinical trial enrolled 158 patients: 80 patients were randomized to receive 0.25% re
- FDA Clears Emergency Use of Comirnaty in Children Aged 5 to 11https://modernod.com/news/fda-clears-emergency-use-of-comirnaty-in-children-aged-5-to-11/2480386/The FDA on Friday authorized emergency use of Pfizer and BioNTech's Comirnaty for the prevention of COVID-19 to include children 5 through 11 years of age. The vaccine is administered as a two-dose primary series, 21 days apart, but at a lower 10-mcg dose than that used for individuals 12 yea
- Amidst the COVID-19 Pandemic, Early Intervention Remains an Obstacle for Overall Eye Health Despite Fear of Blindnesshttps://modernod.com/news/amidst-the-covid-19-pandemic-early-intervention-remains-an-obstacle-for-overall-eye-health-despite-fear-of-blindness/2480352/Globally, most adults, 70 percent, don’t plan to get their eyes examined this year, despite acknowledging the critical importance of eye health. These new findings come from a comprehensive, large-scale Johnson & Johnson Vision Global Eye Health Survey announced in advance of World Sigh